Lung cancer risk unaffected by metformin use in diabetes

August 30, 2012

(HealthDay)—Patients with type 2 diabetes who take metformin do not have a reduced risk of lung cancer, in contrast to previous observational studies, according to a study published online Aug. 24 in Diabetes Care.

To determine whether metformin use in is associated with the incidence of lung cancer, Brielan B. Smiechowski, from the Jewish General Hospital in Montreal, and colleagues analyzed data from 115,923 patients with type 2 diabetes newly treated with oral hypoglycemic agents.

The researchers found that 1,061 patients were diagnosed with lung cancer during follow-up. Based on matching each lung cancer case with up to 10 matched control subjects, metformin had no effect on the lung cancer rate (rate ratio, 0.94). Smoking status had no effect. No dose-response was noted based on number of prescriptions received, cumulative duration of use, and cumulative dose.

"Metformin use is not associated with a decreased risk of lung cancer in patients with type 2 diabetes," Smiechowski and colleagues conclude. "The decreased risk reported in other is likely due to bias from methodological shortcomings."

Explore further: Metformin may lower cancer risk in people with Type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Metformin may lower cancer risk in people with Type 2 diabetes

June 25, 2012
A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results to be presented at The Endocrine Society's 94th Annual Meeting ...

Diabetes linked to lung cancer in postmenopausal women

May 30, 2012
(HealthDay) -- Postmenopausal women with diabetes are at a significantly higher risk of developing lung cancer, particularly if they require insulin therapy, according to research published online May 22 in Diabetes Care.

Thiazolidinediones tied to lower cancer risk in diabetes patients

April 27, 2012
(HealthDay) -- Thiazolidinediones are associated with a lower risk of liver and colorectal cancer in patients with type 2 diabetes, according to a study published in the May issue of Hepatology.

Metformin appeared to slow prostate cancer growth

April 1, 2012
The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Metformin may lower risk for oral cancer development

April 2, 2012
New findings published in Cancer Prevention Research, a journal of the American Association for Cancer Research, suggest that metformin may protect against oral cancer.

Recommended for you

Smart mat detects early warning signs of foot ulcers

August 16, 2017
While completing his residency in anesthesiology at Massachusetts General Hospital in the mid-2000s, Jon Bloom saw his fair share of foot amputations among patients with diabetes. The culprit: infected foot ulcers.

The best place to treat type 1 diabetes might be just under your skin

August 14, 2017
A group of U of T researchers have demonstrated that the space under our skin might be an optimal location to treat type 1 diabetes (T1D).

New measure of insulin-making cells could gauge diabetes progression, treatment

August 10, 2017
Researchers at the University of Wisconsin-Madison have developed a new measurement for the volume and activity of beta cells, the source of the sugar-regulating hormone insulin.

Pioneering immunotherapy shows promise in type 1 diabetes

August 9, 2017
It may be possible to 'retrain' the immune system to slow the progression of type 1 diabetes, according to results of a clinical trial published today in the journal Science Translational Medicine.

Online team-based game helps patients with diabetes lower blood glucose

August 8, 2017
Researchers from Brigham and Women's Hospital and the Veterans Affairs Boston Healthcare System have found that an online, team-based game designed to teach patients about diabetes self-management had a sustained and meaningful ...

Oxidative stress biomarkers don't always signal diabetes risk

August 7, 2017
High levels of compounds found in the body that are commonly associated with oxidative damage may actually be a good sign for some people, according to a recent review of multiple human studies led by an epidemiologist at ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.